ArticleFrontiers in cellular and infection microbiology2026
Taraxacum alleviates ulcerative colitis, accompanied by the modulation of gut microbiota and restoration of intestinal barrier integrity.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have shown that Results: After 14 days of treatment following colitis induction, the herbal extract alleviated body weight loss and pathological abnormalities in the mice. In comparison to the DSS group, the 1.5 g/kg The TM therapy group had markedly elevated levels of colonic T-SOD, T-AOC, and GSH-Px (P < 0.05), alongside a substantial decrease in MDA content (P < 0.05) and inflammatory cytokines (IL-2, IL-6, IFN-g, TNF-a) (P < 0.05). Furthermore, TM markedly elevated the concentrations of volatile fatty acids (acetate, propionate, isobutyrate, and butyrate) in the cecal contents (P < 0.05). The 0.75 and 1.5 g/kg TM groups also elevated the expression of Claudin-1, Occludin, and ZO-1 (P < 0.05), whereas the DSS group showed reduced expression of these mucosal barrier proteins. Concerning gut microbiota, at the Phylum level, the relative abundance of Conclusion: TM alleviated colitis is correlated with enhancing antioxidant capacity, reducing inflammation, restoringbarrier integrity, and modulating the gut microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.